Literature DB >> 20846104

The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death.

Yen-Hung Lin1, Chen Lin, Men-Tzung Lo, Hung-Ju Lin, Yen-Wen Wu, Ron-Bin Hsu, Chia-Lun Chao, Hsiu-Ching Hsu, Pa-Chun Wang, Vin-Cent Wu, Shoei-Shen Wang, Chi-Ming Lee, Kuo-Liong Chien, Yi-Lwun Ho, Ming-Fong Chen, Chung-Kang Peng.   

Abstract

BACKGROUND: Cardiac extra-cellular matrix (ECM) fibrosis plays an important role in the pathophysiology of heart failure (HF). It may provide electrical heterogeneity and a substrate for arrhythmogenicity, which may cause sudden cardiac death (SCD).
METHODS: Twenty-one patients with manifestations of HF and a left ventricular ejection fraction (LVEF) ≤50% were enrolled. The median age was 62 years and median LVEF was 33%. Time- and frequency-domain analysis of heart rate variability (HRV) on 24 h ambulatory electrocardiography recording was assessed. Serum markers of ECM turnover including type I and III aminoterminal propeptide of procollagen (PINP and PIIINP), matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) were analyzed.
RESULTS: The serum PIIINP concentration was correlated significantly with standard deviation of all normal to normal R-R intervals (SDNN) (r=-0.722, p=<0.001), percentage of adjacent NN interval differences >50 ms (pNN50) (r=-0.528, p=0.014), percentage of adjacent NN interval differences >20 ms (pNN20) (r=-0.545, p=0.002), very low frequency (VLF) (r=-0.490, p=0.024), low frequency (LF) (r=-0.491, p=0.024), and high frequency (HF) (r=-0.513, p=0.018). PINP, MMP-2, -9, TIMP-1 were not correlated with time- and frequency-domain analysis of HRV.
CONCLUSIONS: PIIINP was significantly correlated with time- and frequency-domain analysis of HRV in HF patients. PIIINP is a potential serological marker to evaluate cardiac autonomic control and risk of SCD in HF patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20846104      PMCID: PMC3141296          DOI: 10.1515/CCLM.2010.348

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  36 in total

1.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

Authors:  A L Waldo; A J Camm; H deRuyter; P L Friedman; D J MacNeil; J F Pauls; B Pitt; C M Pratt; P J Schwartz; E P Veltri
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

3.  The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve.

Authors:  Neil J Perkins; Enrique F Schisterman
Journal:  Am J Epidemiol       Date:  2006-01-12       Impact factor: 4.897

4.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.

Authors:  R J MacFadyen; C S Barr; A D Struthers
Journal:  Cardiovasc Res       Date:  1997-07       Impact factor: 10.787

5.  The relation of amino-terminal propeptide of type III procollagen and severity of coronary artery disease in patients without myocardial infarction or hibernation.

Authors:  Yen-Hung Lin; Yi-Lwun Ho; Tzung-Dau Wang; Chung-Pin Liu; Hsien-Li Kao; Chia-Lun Chao; Kuo-Liong Chien; Chi-Sheng Hung; Vin-Cent Wu; I-Jung Tsai; Ruoh-Fang Yen; Yu-Chien Shiau; Wen-Jone Chen
Journal:  Clin Biochem       Date:  2006-07-13       Impact factor: 3.281

6.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

7.  Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator.

Authors:  B P Knight; R Goyal; F Pelosi; M Flemming; L Horwood; F Morady; S A Strickberger
Journal:  J Am Coll Cardiol       Date:  1999-06       Impact factor: 24.094

8.  Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes.

Authors:  François Alla; Anna Kearney-Schwartz; Anca Radauceanu; Sylvie Das Dores; Brigitte Dousset; Faiez Zannad
Journal:  Eur J Heart Fail       Date:  2005-09-29       Impact factor: 15.534

9.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2005-09-13       Impact factor: 29.690

10.  Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.

Authors:  Jacob George; Shuki Patal; Dov Wexler; Arie Roth; David Sheps; Gad Keren
Journal:  Am Heart J       Date:  2005-09       Impact factor: 4.749

View more
  3 in total

1.  The relationship between serum fibrosis markers and restrictive ventricular filling in patients with heart failure with reduced ejection fraction: A technetium-99m radionuclide ventriculography study.

Authors:  Yen-Tin Lin; Yen-Hung Lin; Xue-Ming Wu; Chi-Lun Ko; Ruoh-Fang Yen; Ying-Hsein Chen; Ron-Bin Hsu; Chi-Ming Lee; Shoei-Shen Wang; Ming-Fong Chen; Yen-Wen Wu
Journal:  Oncotarget       Date:  2017-01-10

2.  Impact of acute antioxidant supplementation on vascular function and autonomic nervous system modulation in young adults with PTSD.

Authors:  Jennifer B Weggen; Ashley M Darling; Aaron S Autler; Austin C Hogwood; Kevin P Decker; Brandon Imthurn; Gina M Tuzzolo; Ryan S Garten
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-06-02       Impact factor: 3.210

3.  Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.

Authors:  Yi-Yao Chang; Aaron Chen; Xue-Ming Wu; Tse-Pin Hsu; Li-Yu Daisy Liu; Yenh-Hsein Chen; Yen-Wen Wu; Hung-Ju Lin; Ron-Bin Hsu; Chi-Ming Lee; Shoei-Shen Wang; Men-Tzung Lo; Ming-Fong Chen; Yen-Hung Lin
Journal:  Int J Med Sci       Date:  2014-08-13       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.